Accessibility Menu
Ac Immune logo

Ac Immune(NASDAQ) ACIU

Market Cap$289.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-82%
5 Year-60%
1 Year+29%
1 Month+28%
Premium Feature
Moneyball Superscore
51/100
$2.93
+3.17%
+0.09Today
After hours$2.94+$0.01 (+0.17%)
Ac Immune last closing stock price
MetricPriceDate
Last closeUSD 2.842026-09-02
Ac Immune stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.35%USD 2.852026-08-26
1 month+27.93%USD 2.222026-08-03
3 month+18.33%USD 2.402026-06-04
Year to date-9.55%USD 3.142025-12-31
1 year+28.51%USD 2.212025-09-02
3 year-15.98%USD 3.382023-09-01
5 year-60.11%USD 7.122021-09-03
Since inception-81.86%USD 15.662016-09-23

Ac Immune Financials at a Glance

Market Cap

$289.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 17.51M

Net Income (TTM)

-CHF 43.16M

EPS (TTM)

-$0.56

P/E Ratio

-5.11

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$2.93

Volume

171,663

Open

$2.85

Previous Close

$2.93

Daily Range

$2.85 - $3.00

52-Week Range

$2.10 - $4.00

Estimated Earnings Date

Nov 3, 2026

ACIU News

Two people participating in a telehealth session

Why AC Immune Stock Zoomed Almost 15% Higher Today

Eric VolkmanApr 7, 2026
Lab with many colleagues working

Why Shares of AC Immune Jumped This Week

James HalleyJun 30, 2023
brilliant-investment-advisor-showing-client-why-his-biotech-stock-is-higher

Here's Why AC Immune Stock Is Surging Today

Cory RenauerAug 31, 2021
Growth - GettyImages-905948482

Why AC Immune Stock Surged Today

Joe TenebrusoFeb 11, 2021
AD

Why AC Immune Stock Is Crashing Today

George Budwell, PhDSep 23, 2020
Doctor Patient

Here's Why AC Immune Jumped Higher Today

Brian Orelli, PhDJul 16, 2020
ARrow pointing up and down with question mark

Why AC Immune SA Is Imploding

Brian FeroldiJan 30, 2019
multiple lines up

Here's Why AC Immune SA Rose as Much as 21.6% Today

Maxx ChatskoJul 19, 2018

ACIU: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ac Immune

AC Immune S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic agents and diagnostic tools for neurodegenerative diseases. The company utilizes proprietary platforms to create vaccines, antibodies, and small molecules targeting protein misfolding disorders, including Alzheimer's disease.

Products and Services
  • Crenezumab: A monoclonal antibody in Phase II trials for Alzheimer's disease
  • ACI-24: An anti-Abeta vaccine candidate in Phase II evaluation for Alzheimer's disease
  • ACI-35: An anti-Tau vaccine candidate that has completed Phase Ib clinical assessment
Growth Outlook
  • Recent partnerships with industry leaders enhance research capabilities and market reach
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Focus on neurodegenerative diseases presents significant market opportunities
Financial Highlights
  • Q2 2026 revenue of CHF 15.1 million, a notable increase from CHF 1.1 million in Q1 2026
  • Net income of CHF 1.87 million in Q2 2026, marking a positive turnaround
  • Cash and short-term investments totaled CHF 75.4 million as of June 30, 2026
AC Immune S.A. is strategically positioned in the biotechnology sector, focusing on addressing critical unmet needs in neurodegenerative diseases. The company's innovative approach, leveraging advanced platforms, allows for the development of targeted therapies that could significantly impact patient outcomes. Recent financial performance indicates a positive trajectory, with substantial revenue growth and a strong cash position, providing a solid foundation for future development and expansion. The ongoing clinical trials and strategic partnerships further enhance the company's potential for success in a rapidly evolving market.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

122

CEO

Martin Zügel, MD, PhD

Website

www.acimmune.com

Headquarters

Lausanne, VD 1015, CH

ACIU Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-252.25%

Net Income Margin

-246.49%

Return on Equity

-99.17%

Return on Capital

-139.17%

Return on Assets

-28.70%

Earnings Yield

-19.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$289.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

101.77M

Volume

171.66K

Avg. Volume

248.72K

Financials (TTM)

Gross Profit

CHF 17.51M

Operating Income

-CHF 44.17M

EBITDA

-CHF 42.00M

Operating Cash Flow

-CHF 34.79M

Capital Expenditure

-CHF 165.16K

Free Cash Flow

-CHF 34.95M

Cash & ST Invst.

CHF 75.36M

Total Debt

CHF 4.10M

Ac Immune Performance Analysis

Ac Immune annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 4,120,138N/A
20232023-12-31CHF 16,470,229299.7%
20242024-12-31CHF 31,009,43188.3%
20252025-12-31CHF 4,302,299-86.1%
Ac Immune sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-28.1%
Q42025-12-31-64.0%
Q12026-03-31231.1%
Q22026-06-301250.6%
Ac Immune annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -0.89-16.8%
20232023-12-31CHF -0.71-19.6%
20242024-12-31CHF -0.58-18.6%
20252025-12-31CHF -0.8445.2%
Ac Immune sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3023.8%
Q42025-12-3112.5%
Q12026-03-31-7.1%
Q22026-06-30112.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 15.11M

+1057.2%

Gross Profit

CHF 15.11M

+1057.2%

Gross Margin

100.00%

N/A

Market Cap

$289.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.73M

N/A

Employees

106

N/A

Net Income

CHF 1.87M

+108.8%

EBITDA

CHF 1.94M

+109.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 75.36M

-40.7%

Total Debt

CHF 4.10M

-16.6%

Accounts Receivable

CHF 13.65M

+2575.5%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 3.27M

-15.8%

Short Term Debt

CHF 835.00K

-19.6%

Return on Assets

-28.70%

N/A

Return on Invested Capital

-88.05%

N/A

Free Cash Flow

CHF 0.00

+100.0%

Operating Cash Flow

CHF 0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMRNAmarin Corporation plc
$13.71+0.07%
CLLSCellectis S.A.
$3.32+2.15%
LYELLyell Immunopharma, Inc.
$14.32-4.25%
ALDXAldeyra The
$1.48-0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About ACIU

What is the current price of Ac Immune?

Ac Immune is trading at $2.93 per share.

What is the 52-week range for Ac Immune?

Over the past 52 weeks, Ac Immune has traded between $2.10 and $4.00.

How much debt does Ac Immune have?

As of the most recent reporting period, Ac Immune reported total debt of CHF 5.09M.

How much cash does Ac Immune have on hand?

Ac Immune reported CHF 34.41M in cash and cash equivalents in its most recent financial results.

What is Ac Immune’s dividend yield?

Ac Immune does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services